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Abstract 
The potential to bioprint and study 3D bacterial biofilm constructs could have great clinical 
significance at a time when antimicrobial resistance (AMR) is rising to dangerously high levels 
worldwide. In this study, clinically relevant bacterial species including Escherichia coli, 
Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA) and 
Pseudomonas aeruginosa were 3D bioprinted using a double-crosslinked alginate bioink to 
form mature bacteria biofilms, characterized by confocal laser scanning microscopy (CLSM) 
and fluorescent staining. Solid and porous bacteria-laden constructs were reproducibly 
bioprinted with thicknesses ranging from 0.25 to 4 mm. We demonstrated 3D bioprinting of 
thicker biofilms (>4mm) than found in currently available in vitro models. Bacterial viability 
was excellent in the bioprinted constructs, with CLSM observation of bacterial biofilm 
production and maturation possible for at least 28 days in culture. Importantly, we observed 
the complete five-step biofilm life cycle in vitro following 3D bioprinting for the first time, 
suggesting the formation of mature 3D bioprinted biofilms. Bacterial growth was faster in 
thinner, more porous constructs whilst constructs crosslinked with BaCl2 concentrations of 
above 10 mM had denser biofilm formation. 3D MRSA and MSSA biofilm constructs were 
found to show greater resistance to antimicrobials than corresponding two-dimensional (2D) 
cultures. Thicker 3D E.coli biofilms had greater resistance to tetracycline than thinner 
constructs over 7 days of treatment. Our methodology allowed for the precise 3D bioprinting 
of self-supporting 3D bacterial biofilm structures that developed biofilms during extended 
culture. 3D biofilm constructs containing bacterial biofilms produce a model with much 
greater clinical relevance compared to 2D culture models and we have demonstrated their 
use in antimicrobial testing.  
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 3 
Introduction 
Biofilms can be defined as 3D structured communities of bacterial cells enclosed in a self- 
produced polymeric matrix, attached to a solid surface or substratum [1]. Bacterial biofilm 
formation is crucial to establishing chronic infections including respiratory infection[2]. 
orthopaedic infection [3], heart valve infection (endocarditis) [4], and nosocomial infections 
[5]. In the case of acute infections, bacteria often exist in the planktonic (or free-swimming) 
state, allowing effective treatment with antimicrobials. However, once a biofilm develops 
infections are known to be 10-1000 times more resistant to antimicrobial agents, often 
rendering standard antimicrobial therapy ineffective without more invasive treatment such 
as surgery [6]. In the United States of America alone, there are 17 million new biofilm-
associated bacterial infections that lead to estimated health care costs of $94 billion and 
550,000 deaths each year [7]. According to the World Health Organization (WHO), urgent 
action is required to avoid a “post-antibiotic era”, in which common infections and minor 
injuries can once again kill; antimicrobial resistance is projected to result in 10 million deaths 
every year globally by 2050 [8]. Global concern about AMR is compounded by the fact that it 
has been 30 years since a new class of antibiotics was last introduced [9]. Therefore, 
increasing importance is being placed on drug screening, and in particular, antimicrobial 
susceptibility testing (AST), which requires suitable models that more closely resemble in vivo 
biofilm formation.  
The minimum inhibitory concentration (MIC) of antimicrobial agents (defined as the lowest 
concentration of an antimicrobial agent at which visible bacterial growth is inhibited after 
overnight incubation) is frequently calculated during AST to assess antimicrobial efficacy and 
bacterial resistance [10]. Methods to determine the MIC based on 2D planktonic cultures of 
bacteria are well established [11]. However, determining the minimal biofilm eradicating 
concentration (MBEC) in biofilm infections is much more challenging. This is primarily because 
in vivo biofilm formation is three dimensional (3D) in architecture, which differs to most 
currently available laboratory models that tend to involve 2D biofilm culture [12-14]. AST of 
planktonic bacteria therefore tends to give misleading results that do not reflect the increased 
resistance of bacteria living in a 3D biofilm [15, 16]. This has significant clinical implications; 
for example, antimicrobial agents are usually chosen on the basis of their efficacy against 2D 
planktonic cultures which are more sensitive to treatment than 3D biofilms. Clinically this is 
well demonstrated by cystic fibrosis patients, where treatment of P.aeruginosa infection with 
antibiotics originally developed against planktonic cultures often becomes ineffective once 
biofilm formation occurs [15]. To develop novel antimicrobials capable of disrupting biofilm 
formation and resistance in future, 3D in vitro biofilm models more representative of clinical 
infection are required.  
Most commonly used 2D biofilm culture methods attempt to simulate the nature of the in 
vivo environment by focussing on selected relevant factors such as materials, nutrients and, 
importantly, fluid flow including drip flow [16], rotating disk [17], microfluidics [18], and flow 
chamber architecture [19]. Unfortunately, none of these methods mimic the complexity of 
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 4 
the 3D microenvironment and host defence mechanisms [20] and unable to produce biofilm 
thicknesses beyond 100 µm [21, 22]. In contrast to the current in vitro models, in vivo biofilms 
can grow beyond 1000 µm in size and are often found embedded within a host’s extracellular 
matrix, leading to interactions with the host immune system which can further alter biofilm 
morphology and size [1, 23]. 
3D bioprinting has developed rapidly as a technique that can deposit living cells and 
biomaterials in user-defined patterns to build complex tissue constructs “from the bottom 
up” [24-27]. While there are elegant approaches on 3D bioprinting bacteria and their 
aggregates [28-32], there has been no report on demonstrating the formation of mature 
bacteria biofilms. However, the capacity to reliably and reproducibly 3D bioprint bacterial 
biofilms have several potential benefits.  Embedded bacteria have been shown to have 
increased metabolic activity, AMR and plasmid stability compared to bacteria grown in [33, 
34]. 3D bioprinted bacterial biofilms therefore could potentially mirror in vivo bacterial 
growth and behaviour more closely than traditional 2D models, increasing the potential to 
investigate critical bacterial quorum sensing (QS) and antimicrobial biofilm penetration [34, 
35]. 3D bioprinting also increases the potential to produce biofilm constructs with 
predesigned dimensions, with a high degree of control possible over biofilm thickness and 
dimensions. Other benefits of 3D bioprinting biofilm include the potential creation of 
microbial fuel cells [36], biosensors [37] and biotechnological applications [37-39]. 
In this paper, we present a novel 3D bioprinting biofilm technology and report the first 
investigation of the formation of mature bioprinted 3D biofilms and measure their responses 
to antibiotic drug tests, and drug penetration.  Mature biofilms with different thicknesses and 
structures were designed and bioprinted using a range of clinically relevant bacterial strains. 
In vitro AST was performed to compare the resistance of 2D cultures versus 3D printed biofilm 
constructs for the first time. Bioprinting of biofilm constructs with thicknesses greater than 
previously available in vitro models was also successfully performed.  
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Materials and Methods 
Bacteria-laden bioink preparation 
Brain Heart Infusion (BHI) broth (Sigma-Aldrich, UK) powder was dissolved in sterile deionized 
water to produce a 37 g/ L BHI Broth and then autoclaved. UV-sterilised sodium alginate 
powder (Protanal LF10/60FT, FMC Biopolymer, UK) was then dissolved in BHI Broth to 
produce a 4% (w/v) alginate solution. The alginate solution was subjected to magnetic stirring 
until reaching homogeneity and then sterilised through heating to boiling point (95°C) three 
times. Solutions consisting of 4% w/v sodium alginate and 0.4% w/v CaCl2 were then mixed 
with a volume ratio of 1:1 to create a partially cross-linked 0.2% CaCl2: 2% sodium alginate 
hydrogel in a 50 mL conical tube. The hydrogel solution was vortex mixed at room 
temperature at 1500 rpm for 5 min to produce a homogeneous, partially cross-linked alginate 
hydrogel. Alginate hydrogels were then stored at 4 °C prior to usage to prevent the growth of 
contaminants.   
Bacterial strains and growth media 
Bacterial strains were universally cultured in Brain Heart Infusion (BHI) broth at 37oC whilst 
shaking. Strains used included Escherichia coli (E.coli clinical isolate, ATCC 25922), 
Pseudomonas aeruginosa (P. aeruginosa, PAO1, wild type strain, ATCC 47085), Methicillin-
sensitive staphylococcus aureus (MSSA, clinical isolate, ATCC 29213) and Methicillin-resistant 
staphylococcus aureus (MRSA, clinical isolate, ATCC 700788). Chosen strains were routinely 
maintained on BHI agar (Sigma-Aldrich, UK) plates and stocks kept frozen in glycerol (50% v/v) 
at -80oC.  
Inoculum preparation  
Bacterial strains taken from glycerol stocks were streaked on to a BHI agar plate and 
incubated at 37oC overnight. The following day a single colony was inoculated into 5 mL of 
BHI broth and incubated overnight at 37oC, with 200 rpm shaking (Mini shaker, Cleaver). The 
overnight cultures were harvested in the stationary phase after 18 h cultivation. The bacteria 
were collected by centrifugation (3,000 rpm, 4oC, 5 min) and washed three times with 9% 
sodium chloride (NaCl) to remove the residual BHI medium. In all experiments, the 
concentration of bacteria was determined by optical density spectrometry (Eppendorf 
BioPhotometer) and inoculated to 1.0 at wavelength 600 nm (OD600nm=1.0). The inoculated 
suspension of each strain was prepared in 10 mL of 9% NaCl in a 50 mL centrifuge tube (Fisher 
Scientific, UK) and the cells harvested by centrifugation (3,000 rpm, 4oC, 5 min). Bacterial cell-
pellets were then re-suspended in 500 µL of 0.2% CaCl2: 2% sodium alginate hydrogel solution 
with a micropipette and dispensed into a 5 mL Luer-lock syringe (Fisher Scientific, UK). 
Connection to a further 5 mL Luer-lock syringe containing 4.5 mL 0.2% CaCl2: 2% sodium 
alginate hydrogel warmed to 37°C allowed repeated, gentle mixing to be carried out back and 
forth between syringes containing bacteria and hydrogel (100 mixes back and forth), 
producing 5 mL bioink with homogeneously distributed bacteria.  
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Construct design 
3D models consisting of a solid or lattice 10 mm x 10 mm square design with increasing 
vertical thicknesses (0.25 mm, 0.5 mm, 1 mm, 2 mm, 4 mm) were produced using Autodesk® 
Netfabb® software (Autodesk®, Inc, USA) and exported as an STL file.  Open-source slicer 
software (Sli3er, Version 1.2.9) was used to load the STL files and generate G-code files using 
the following settings for bioprinting: layer thickness, 0.1 mm; infill pattern, rectilinear; infill 
density, 25%; speed, 10 mm/s; extrusion multiplier 1.2. G-code files corresponding to solid 
and lattice constructs with differing vertical thicknesses were then loaded onto the bioprinter.  
Bioprinting  
A three-axis (X-Y-Z), single nozzle 3D cell printer developed in our laboratory was used for 
bioprinting bioinks laden with different bacteria. This bioprinter represents an adapted, 
extrusion-based version of a previously developed microvalve-based bioprinter used in our 
lab to bioprint human cells including induced pluripotent stem cells [26, 39, 40]. Briefly, the 
bioprinter produces 3D constructs by coordinating the motion of a mechanically-driven 
syringe. The dispenser deposits extrudate consisting of hydrogel on a stationary Z-platform. 
As successive layers of extrudate are deposited, the z-platform moves downwards allowing 
structures to be bioprinted from the bottom up, layer-by-layer. Prior to use, the bioprinter 
was sterilized via UV exposure and wiped down with 70% ethanol. Sterility was maintained 
during bioprinting by placing the bioprinter in a laminar flow cabinet. Sterile 5 mL Luer-lock 
syringes containing bacterial bioink were attached to 25G printing nozzles and loaded into the 
bioprinter, allowing bioprinting into sterile 6-well culture plates to occur.   
Secondary cross-linking of constructs 
Ethylenediaminetetraacetic acid (EDTA), calcium chloride (CaCl2) and barium chloride (BaCl2) 
powders (Sigma-Aldrich, UK) were sterilised with ultraviolet (UV) light (three 30 min cycles). 
Solutions of 0.4% w/v CaCl2, 10 mM BaCl2, 20 mM BaCl2, 40 mM BaCl2 and 110 mM EDTA 
(Sigma-Aldrich, UK) were prepared in sterile deionised water. All solutions were then 
autoclaved at 121 °C for 30 minutes prior to experimental usage. 
Following bioprinting, constructs were cross-linked by submersion in ionic solutions of either 
10, 20 or 40 mM BaCl2 for 2 mins. Cross-linked constructs were then rinsed in phosphate-
buffered saline (PBS) prior to incubation in BHI medium under standard culture conditions (37 
°C, 5% CO2, and 95% relative humidity). BHI media was replenished every second or third day 
and culture was performed atop a compact fixed-angle platform rocker (Grant Bio™ PMR-30 
Compact Fixed-Angle Platform Rocker, Fisher Scientific, UK), to increase flow of media around 
the bioprinted constructs.  
Fluorescence staining for biofilm viability 
A commercial Film TracerTM LIVE/DEADTM biofilm viability kit (Thermo Fisher) was used for the 
assessment of biofilm viability based on staining with the membrane potential sensitive dye 
propidium iodide (PI) (490 nm excitation, red emission) and the nucleic acid stain SYTO-9 (488 
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nm excitation, green emission). In principle, bacteria with intact cell membranes stain 
fluorescent green, whereas bacteria with damaged membranes stain fluorescent red. Cell 
viability staining of bacteria was carried out by incubating biofilm constructs concomitantly 
with SYTO-9 (6.7 µM) and PI (40 µM) in 35 mm glass bottomed imaging dishes (Ibidi) at room 
temperature (RT) for 45 min to allow stain penetration.  
Biofilm morphotype analysis  
In this study, a Leica Microsystems TCS SP8 CARS microscope utilising a 25x objective (HC 
FLUOTAR L 25x/0.95 W) was used for all confocal fluorescence imaging measurements.  To 
minimise or eliminate artefacts associated with simultaneous dual wavelength excitation, all 
dual labelled biofilms were sequentially scanned, frame-by-frame, first at 488 nm (Argon 
laser, 70 µW) then at 561 nm (DPSS laser, 80 µW). Line averaging (x2) was used to capture 
images with reduced noise. Fluorescence emission was then sequentially collected in the 
green and red regions of the spectrum respectively. Images were captured in a two-
dimensional (2D) projection. For analysing spatial separation in the z-direction (thickness), 
step sizes between 40-140 µm were used and 3D reconstructions were performed using Leica 
imaging software (LAS X).  Five image stacks were (typically 700 x 700 µm images over a depth 
of 40 - 140 µm) were acquired randomly from three independent constructs per BaCl2 
concentration per time point (15 stacks in total). The image stacks were then analysed using 
MATLAB 2016A software. 
Antibiotic susceptibility testing (AST) 
For all AST methods, inocula of the isolate tested were prepared according the inoculum 
preparation protocol described above. 
The methicillin stock solution of 20 mg/mL was prepared in sterile dH2O and diluted in BHI 
broth to obtain solutions with preliminary concentration in a range of 2.5 to 10 mg/mL. 
Investigation of the response of 3D biofilm constructs to methicillin was then made by initially 
culturing porous, 1 mm constructs containing MRSA or MSSA for 14 days to allow biofilm 
maturation to occur. The matured biofilm constructs were then transferred to sterile 
Corning 6-well microtiter plates (Sigma-Aldrich, UK). A 3 mL volume of each methicillin 
solution was dispensed into each well of the plate. Fresh BHI broth was then added without 
antibiotic into the positive control wells. The plates were sealed with an anaerobic film 
(Thermo Fisher Scientific, UK) and incubated under anaerobic conditions at 37oC for 24 h.  
2D Broth microdilution method  
Corning 96-well microtiter plates (Sigma-Aldrich, UK) were used for determining the MICs of 
the antimicrobial agents methicillin sodium salt (Sigma-Aldrich, UK). A methicillin 
concentration in a range of 0.02 to 5 mg/mL were used. The MRSA and MSSA inoculum plural 
(OD1.0) were prepared as described above. A 50 µL volume of each methicillin solution and a 
50 µL of inoculated suspension were dispensed into each well of the microtiter plates 
respectively. The 96-well plates were then sealed with an anaerobic film (Thermo Fisher 
Scientific, UK) and incubated under anaerobic conditions at 37oC for 24 hours. The optical 
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 8 
density of inoculated culture wells was then measured using a plate reader (Multiskan Go, 
Thermo Scientific). Subsequently, MICs were read as the lowest concentration of an 
antimicrobial agent at which visible growth was inhibited. 
3D Broth macrodilution method  
Methicillin stock solution of 20 mg/mL was prepared in sterile dH2O and diluted in BHI broth 
to obtain solutions with preliminary concentrations ranging from 2.5 to 10 mg/mL. 
Investigation of the response of 3D biofilm constructs to methicillin was then performed by 
exposing a series of porous, 1 mm MRSA or MSSA constructs to increasing concentrations of 
methicillin. MRSA and MSSA constructs were cultured for 14 days prior to methicillin exposure 
to allow biofilm maturation to occur. Mature MRSA and MSSA biofilm constructs were then 
transferred into sterile Corning® 6-well plates (Sigma-Aldrich, UK) and incubated in 3 mL 
volumes of either 2.5, 5 or 10 mg/mL methicillin solution. Positive-control wells containing 
fresh BHI broth, no methicillin and MRSA or MSSA constructs were also set up. The 6-well 
plates were sealed with an anaerobic film (Thermo Fisher Scientific, UK) and incubated under 
anaerobic conditions at 37oC for 24 hours. The optical density of inoculated culture wells was 
again measured using a plate reader (Multiskan Go, Thermo Scientific). 
Biofilm antimicrobial penetration test 
3D bioprinted E.coli biofilm constructs of 1mm and 2mm thickness and porous design were 
cultured for 5 days to allow significant biofilm formation to occur. Biofilm constructs were 
then washed x3 with phosphate buffered saline (PBS) solution to remove non-adherent 
bacteria. Antibiotic disks containing 30 µg tetracycline (Oxoid, UK) were then placed on top 
of E.coli biofilm constructs and incubated at 37oC for 7 days within BHI broth.  The tetracycline 
disks located on top of the biofilm constructs were replaced daily to maintain consistent 
delivery of antibiotic.   
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Results and discussions 
Developing long-term stability of bioprinted alginate hydrogels to allow observation of 3D 
biofilm formation 
The schematic presented below (Scheme 1) elucidates our general methodology of bacterial 
biofilm bioprinting using a biocompatible bioink [40, 41], extrusion bioprinting and a step-
wise ionic crosslinking process. Cultured bacteria were mixed into a partially-crosslinked 
hydrogel to produce a bioink with homogenous bacterial concentration. A home-built 
bioextrusion based bioprinter was then used to extrude the bioink to produce constructs with 
predesigned dimensions. Following bioprinting, secondary ionic cross-linking of the hydrogel 
was performed to increase construct stability, allowing prolonged culture and observation 
(up to 28 days).   
 
Scheme 1: Schematic of bacterial biofilm bioprinting process. Initial designs to be bioprinted 
were produced using computer-aided design (CAD) software. Following this, a partially cross-
linked hydrogel was produced by mixing sodium alginate and calcium chloride (CaCl2) 
together. Bacteria were then mixed into the hydrogel to produce a bioink with homogenously 
distributed bacteria. 3D bioprinting was then performed, using a custom-built bioprinter that 
uses mechanical force to extrude bioink from a syringe that is moved in the x-y-z plane. 
Bioprinted constructs of solid and porous design were then immersed in solutions of barium 
chloride (BaCl2) for 2 mins to secondary cross-link the constructs. Following bioprinting and 
immersion cross-linking, the constructs were cultured in bacterial growth media, allowing 
analysis to be performed at selected time points.   
The complex structure of 3D biofilms found in clinical infection take significantly longer to 
develop and mature than the simpler, 2D biofilm in vitro models which can be produced in 
overnight laboratory culture [3, 42]. Achieving sufficient stability in bioprinted bacterial 
construct was therefore essential to allow time for bacteria to associate, proliferate and 
deposit their own extracellular polymeric matrix to form a mature 3D biofilm structure. 
Alginate is a widely-adopted hydrogel for bioprinting and was chosen as the main component 
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of our bacterial bioink due to its biocompatibility, low toxicity, low cost and ease of use [25, 
43, 44]. 
In previous work we have developed the stability of alginate bioinks to allow the successful 
long-term 3D cell culture and differentiation of stem cells [25, 44]. This was achieved by 
double cross-linking alginate with calcium and then barium cations in a stepwise process [44]. 
We adapted this approach to produce double cross-linked bacterial bioink constructs with 
extended stability (>4 weeks) in culture. Other cations including strontium have been utilized 
elsewhere for this purpose; however, barium has been shown to give the strongest cross-
linking effect, optimizing construct mechanical stability [45]. Initial cross-linking of sodium 
alginate hydrogel with calcium chloride created a hydrogel with sufficient viscosity to allow 
successful bioprinting of free-standing structures of both solid and porous design, ranging in 
thickness from 0.25 mm to 4 mm (figure 1a). By performing alginate hydrogel cross-linking 
prior to bioprinting, rather than extruding alginate onto a calcium-coated culture surface as 
performed in other literature, homogenous hydrogel cross-linking was achieved; this is 
essential to achieve good printability [28]. Further cross-linking occurred following bioprinting 
by exposure to solutions of barium chloride which further helped to maintain construct 
stability, extending the stability of constructs from within a week (with calcium-only cross-
linking) to over 4 weeks in culture. (ESI, figure S1, figure S2). Bioprinting resolution with the 
hydrogel was sufficient to produce more intricate structures using a 32 g printing needle, 
corresponding to a 108 µm inner needle diameter (figure 1b).  
Confocal laser scanning microscopy (CLSM) was used to observe 3D bioprinted biofilm 
formation. Standard light microscopes often struggle to image biofilm of more than 3-4 µm 
thickness as biofilm material above and below the focal plane tend to scatter light and 
interfere with direct measurement [46]. Contrastingly, CLSM allows optical sectioning of 
biofilms and, with image analysis, 3D reconstruction is possible [47]. 
The extended hydrogel stability after bioprinting allows observation of 3D biofilm formation 
for several weeks. Previous attempts reported elsewhere in the literature to 3D bioprint 
bacteria only demonstrated bacterial viability up to a maximum of 7-9 days, with no attempts 
made to perform antimicrobial testing on 3D bioprinted bacterial constructs [28, 30, 31]. The 
stability in culture of the bioprinted hydrogel-bacteria construct achieved in our study is 
therefore significant, as it allows for extended observation of bacterial growth as well as 
offering the potential to perform antimicrobial studies and further analysis of biofilm 
formation in 3D.  Clinical biofilm infections are most often chronic in nature and develop over 
a period of weeks and even months; the stability of our bioprinted constructs may therefore 
facilitate greater potential to mirror clinical biofilms than currently available biofilm models 
[3, 7, 15, 48, 49]. 
Investigating the influence of construct design and thickness on biofilm formation 
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In order to mimic in vivo biofilms and to create an ideal in vitro 3D bioprinted biofilm model, 
solid and porous constructs were bioprinted in a range of thicknesses from 0.25 mm to 4 mm 
to investigate the ideal construct design and thickness for E. coli biofilm formation. 
E. coli biofilm formation (or bacterial density) was greater in thinner (0.25 mm to 1 mm), 
constructs compared to thicker (4mm) construct designs (p<0.001, ANOVA) (figure 1c). 
However, thinner constructs of 0.25 mm and 0.5 mm thickness were not robust enough to 
allow physical manipulation and CLSM imaging to be performed after 14 days culture. This 
was presumed to be due to leaching of cations (Ca2+ and Ba2+) from the thin, relatively high-
surface area constructs into surrounding culture media, resulting in decreased cross-linking; 
this is likely to have been exacerbated by regular media changes and culture atop a rocking 
device, increasing outwards diffusion of cations from the hydrogel-bacteria construct. In 4 
mm thick constructs, reduced biofilm formation was observed in solid compared to porous 
constructs (p=0.038, t-test) (figure 1c).   
We believe the porous construct design facilitates convective fluid transport through the pore 
channels, enhancing nutrient and oxygen diffusion processes in comparison to non-porous, 
solid constructs. This would explain why the aerobic bacteria E.coli failed to proliferate and 
produce significant biofilm in the thick, solid constructs, with the optimal structure for E.coli 
being a 1 mm porous construct. 
Page 11 of 23 AUTHOR SUBMITTED MANUSCRIPT - BF-101917.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 12 
  
Page 12 of 23AUTHOR SUBMITTED MANUSCRIPT - BF-101917.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 13 
Figure 1. Thickness, structure and cross-linking of bioprinted constructs influences biofilm 
formation. (a) Solid and porous constructs with vertical thicknesses increasing from 0.25 mm 
to 4 mm were sequentially bioprinted and cross-linked by exposure to 20 mM BaCl2. 
Measured thickness correlated well with designed vertical thickness after measurement with 
digital callipers (ESI, Table 1). (b) Hydrogel printability was such that intricate structures could 
be printed with a 32G, 0.108 µm inner needle diameter needle. (c) 3D reconstructed CLSM z-
stack images were acquired, allowing comparison of biofilm growth in solid and porous 
structures. Initial analysis at 5 days found that growth in solid constructs was slower than in 
corresponding porous constructs in all ranges of thicknesses. At day 14, 1 mm constructs 
appeared to have the greatest biofilm formation, whilst 0.5 mm and 0.25 mm constructs had 
insufficient mechanical stability to allow analysis. The sizes of the scale bars in the photograph 
and fluorescence images are 1 centimetre and 100 microns. 
Bioprinting of thick, anaerobic 3D biofilm constructs 
Whilst the aerobic bacteria E. coli had limited growth in thicker bioprinted constructs (figure 
1c), presumably due to limited diffusion of nutrients and oxygen, anaerobic bacteria have 
greater potential to thrive in oxygen-deplete conditions. As an opportunistic, nosocomial 
pathogen of immunocompromised individuals, the anaerobic strain Pseudomonas aeruginosa 
(P. aeruginosa) is well known for infecting the thick, oxygen-depleted mucus in the airways of 
cystic fibrosis (CF) patients, producing robust in vivo biofilms [2]. The culture conditions 
provided by the thick respiratory mucus in CF patients is somewhat analogous to those 
provided by our thick, non-porous hydrogel constructs. To investigate this, in vitro biofilm 
formation of P. aeruginosa (figure 2) was examined in non-porous, thick (2 mm and 4 mm) 
constructs (figure. 2).  
 
Figure 2. Pseudomonas aeruginosa (PAO1) formed anaerobic biofilms in thick constructs. 
(a) Photo images of 3D bioprinted PAO1 biofilm at day 0 (white colour) and matured biofilm 
at day 14 (blue-green colour). (b) 3D reconstructed CLSM Z-stack in 2D-projection and 3D 
reconstructed images (1:1 aspect ratio in x, y & z axes) of matured PAO1 biofilm formed at 2 
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mm and 4 mm thickness at day 14. The sizes of the scale bars in the photograph and 
fluorescence images are 1 centimetre and 100 microns. 
P.aeruginosa was observed to undergo extensive colonisation and aggregation in 2 mm and 
4 mm thick, non-porous structures, forming an extremely dense layer of biofilm (figure 2b). 
In contrast, much more limited bacterial growth and biofilm formation was observed via CLSM 
in 2 mm and 4 mm constructs inoculated with the aerobic bacteria E. coli (figure 1c). Strong 
blue-green pigmentation was also seen to form in 2 mm and 4 mm P.aeruginosa constructs 
over 14 days of culture (figure 2a); this is likely related to the expression of  two metabolites, 
pyocyanin (blue) and pyoverdine (green), which is known to occur in P.aeruginosa to facilitate 
anaerobic respiration [50]. The prevalence of multidrug-resistant (MDR) anaerobes, including 
P. aeruginosa, is increasing worldwide with limited current therapeutic options [51, 52].  The 
extensive growth of P.aeruginosa and associated biofilm formation seen within our 3D 
bioprinted constructs therefore offers a novel and highly promising in vitro method of 
studying anaerobic bacterial biofilm infection. 
Capturing the in vitro life cycle of biofilm in 3D 
Biofilm formation is reported to occur in a five-step lifecycle (figure 3a), which begins with 
the attachment of planktonic cells to a biological or inert surface and culminates in mature 
biofilm formation[53]. However, due to factors including limited biofilm thickness, current in 
vitro models are unable to readily facilitate observation of the five-step process and complex 
microarchitecture development that occurs during biofilm formation [54].  
As illustrated in figure 3a, Initially, ① free swimming planktonic bacteria were attached on 
the surface, ② Soon after, bacteria began to divide and aggregate together in small 
microcolonies and secrete quorum signals ③, which initiated up-regulation of various genes 
and virulence factors on a community-wide basis. Bacteria cells forming an extracellular 
biofilm matrix ④ by secrete copious polymers including polysaccharides, proteins and 
oligonucleotides. Biofilm continues to accumulate and consuming ambient nutrient and QC 
acceptors. As results of increased in shear stress and other cell signalling events, portions of 
biofilm started detaching or slough off ⑤ entirely. Dispersed cells can quickly revert to their 
planktonic form to colonise other sites, whilst retaining properties such as AMR [54].  
The influence of BaCl2 cross-linking concentration on bacterial growth was also analysed over 
28 days by exposing porous, 1 mm constructs containing MRSA to a range of BaCl2 
concentrations (ESI, figure S3). Growth within all constructs was initially strong; however, it 
was perceptible that bacteria had a greater tendency to leach from constructs exposed to 10 
mM BaCl2, with greater biofilm formation seen in 20 mM and 40 mM constructs (figure 3c). A 
custom designed image processing algorithm, implemented in MATLAB2016a, was used to 
apply further statistical analysis to quantify biofilm formation (ESI, figure S4, figure S5). It was 
found that 10 mM of BaCl2 provided less favourable conditions for biofilm formation 
compared to 20 mM and 40 mM constructs between days 4 and 23 (p<0.001, ANOVA). This 
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was presumed due to reduced cation (Ba2+) cross-linking density allowing greater leaching of 
bacteria.  
 
Figure 3. 3D reconstructed confocal laser scanning microscopy (CLSM) Z-stacks of 3D 
bioprinted biofilm images (a) The 5-step process of biofilm formation in 2D correlated with 
(b) cross-sectional and side-on CLSM images of 3D bioprinted biofilm formation. (c) Growth 
of MRSA in 1 mm, porous scaffolds exposed to increasing concentration of BaCl2 from 10 mM 
to 40 mM was examined over a 28 day period. Schematic (a) adopted from V. E. Wagner et al 
[2]. The sizes of the scale bars in the photograph and fluorescence images are 1 centimetre 
and 100 microns. 
CLSM studies demonstrated superior biofilm formation in 10 mM, 20 mM and 40 mM 
constructs, with significant biofilm formation evident after 5 days. Initially, ① individual 
planktonic bacteria were homogenously distributed in bioink at day 0 (figure 3c, Day 0). 
Although some bacteria may have left the construct, a high density remained and likely 
adhered to the bioink scaffold using cell surface displayed adhesin molecules.  ② soon after, 
bacteria began to divide and aggregate together in small microcolonies (figure 3c, Day 1-2) 
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with in the construct, which merged into larger communities (figure 3c, Day 3-5); ③ 
progressive deposition of an EPS matrix also occurred, ④ leading to mature biofilm formation 
(figure 3c, Day 14). Eventually, ⑤ regions of biofilm were seen to spontaneously disperse 
between days 23 and 28 as bacteria enzymatically dissolved the extracellular matrix [55], 
weaken the biofilm structure and release microbial cells spread and leak out of the construct 
(figure 3c, Day23-28) into surrounding culture media (where new biofilms can be formed). It 
is important to observe that 3D bioprinted alginate constructs remains largely intact while the 
bacteria escaped from constructs (ESI, Figure S2) after day 23. This further confirms that the 
lower microbial cell density observed from Day 23-28 was consistent with the final stage of 
the biofilm lifecycle where bacteria leak out of the biofilm and spread rather than the 
degradation of the 3D alginate constructs. 
To the best of our knowledge, we have demonstrated for the first time the processes involved 
in mature 3D biofilm formation in vitro over a 28-day period using bioprinting (figure 3c). This 
allows direct correlation to the 5-step process governing biofilm formation in 2D to be made 
(figure 3a). 
Comparison of 2D vs 3D in vitro antimicrobial susceptibility testing (AST) 
To compare the susceptibility of 2D and 3D bacterial cultures to treatment, we utilised 3D 
bioprinted biofilms as an in vitro model with comparison made to 2D bacterial cultures. 
Staphylococcus aureus (S. aureus) was chosen for investigation as a major human 
pathogen[56]. Although most commonly associated with skin and soft tissue infections, S. 
aureus is also responsible for a range of serious invasive infections, including osteomyelitis, 
necrotising pneumonia, endocarditis and bacteraemia [56]. Infections caused by S. aureus are 
increasing worldwide, with over 52% of intensive care unit (ICU) infections reported to be 
caused by S.aureus [57]. Most strains of S.aureus, including methicillin-susceptible S.aureus 
(MSSA), are sensitive to β-lactam antibiotics and are responsive to treatment.  However, there 
is a growing worldwide prevalence of methicillin resistant S. aureus (MRSA) infections, which 
have repeatedly been associated with a worse patient outcome compared to infections 
caused by methicillin sensitive S. aureus (MSSA) [58]. Furthermore, the efficacy of first-line 
treatments for MRSA such as vancomycin is dwindling [59]. Antibiotic resistance studies are 
therefore essential to allow the development of novel anti-biofilm therapies against MRSA 
and MSSA biofilms.  
The broth microdilution method was used to determine the lowest concentration (MIC) of 
methicillin antibiotic that prevented visible growth of MRSA and MSSA in 2D culture (figure 
4a). The broth macrodilution method was then used to determine the minimal biofilm 
eradicating concentration (MBEC) in 3D bioprinted MRSA and MSSA biofilm culture models 
(figure 4c). The MIC and MBEC were determined by a visual inspection of culture wells and 
correlated with measurements of absorbance of light through treated culture wells in both 
cases (figure 4b & 4d). Due to resistance to methicillin, MRSA had a higher MIC than MSSA in 
2D (figure 4a) and a higher MBEC than MSSA in 3D culture as expected (figure 4c). However, 
for both MRSA and MSSA, the MBEC calculated in 3D culture was significantly higher than the 
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MIC for 2D culture. Whilst 0.16 μg/mL methicillin prevented visible growth of 2D MSSA 
culture, the MBEC for MSSA in 3D culture appeared to be at least 15 times higher at 2.5 
mg/ml. Similarly, although 1.25 μg/mL methicillin appeared to prevent 2D growth of MRSA, 
growth of MRSA in 3D culture still occurred with greater than 10 mg/ml methicillin. Therefore, 
for both MRSA and MSSA, a far higher dose of methicillin was required to treat biofilm growth 
than was required to treat 2D infection. This result is in keeping with previous reports 
suggesting that biofilm formation can cause a 10 to 1,000-fold increase in bacterial tolerance 
to antimicrobial treatment compared to 2D, planktonic cultures [33, 55].  
 
Figure 4. In vitro antimicrobial susceptibility testing (AST). (a) The MICs were determined by 
broth microdilution methods. An MIC of methicillin of 0.16 μg/mL was required to prevent 
visible growth of MSSA, whilst for MRSA the MIC of methicillin was 1.25 μg/mL (figure 4a). (b) 
Optical density measurement of the methicillin-containing culture. No significant change in 
absorbance was observed when methicillin concentrations were increased beyond the MIC 
calculated for MRSA or MSSA in 2D. (c) The MBECs were determined by broth macrodilution 
method. MBECs appeared to be at least 2.5 mg/mL for MSSA, and greater than 10 mg/mL for 
MRSA on inspection. (d) Measurement of the light absorbance of the culture broth 
surrounding the MRSA and MSSA constructs supported these findings, with far higher doses 
of methicillin required to reduce bacteria growth and therefore the measured broth light 
absorbance than in 2D cultures. 
Biofilm thickness influences response to treatment 
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AST methods such as MIC calculation do not distinguish between bactericidal and 
bacteriostatic effects of antibitoics, and crucially do not provide information on the degree of 
antimicrobial biofilm penetration or eradicaiton [1, 4, 50, 60-64]. Utilising 3D bioprinted 
biofilms as an in vitro model, we sought to investigate the relationship between bacterial 
biofilm thickness and susceptibility to antimicrobial treatment. Sensitivity of E. coli to 
tetracycline was first confirmed in 2D culture (ESI, figure S6). Bioprinted E.coli constructs of 1 
and 2 mm thickness were then grown for 5 days to allow biofilm maturation, before exposure 
to 30 µg tetracycline discs which were changed every 24 h for seven days, mimicking a course 
of clinical antimicrobial treatment (figure 5a). It was apparent that 2 mm constructs remained 
opaque whilst 1 mm constructs became increasingly transparent in response to tetracycline 
exposure (figure 5a). CLSM imaging of the constructs after 7 days of tetracycline exposure 
demonstrated that E.coli biofilms had greater viability in 2 mm constructs, whilst bacteria 
located below the tetracycline disc in 1 mm constructs had largely been destroyed (figure 5b).  
As discussed previously, current methods of studying antimicrobial biofilm penetration and 
eradication suffer significant limitations. However, 3D bioprinted biofilms could offer hope 
for a novel and reproducible method of studying antimicrobial biofilm penetration and 
eradication in 3D. In the clinical environment 3D bioprinted biofilms could feasibly be 
generated from bacterial samples taken from patients in a similar manner to our experiment; 
this would allow antimicrobials to be selected on the basis of their ability to achieve biofilm 
penetration and eradication in patient-specific infections. Furthermore, it is recognised that 
3D cultures (such as our 3D bioprinted biofilm) more closely resemble the in vivo biofilm, 
when compared to traditionally used 2D in vitro cultures [15, 64-66]. 
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Figure 5. Biofilm thickness determines response to treatment (a) 1 mm and 2 mm thick 
constructs containing E.coli were bioprinted and allowed to mature for 14 days before 30 µg 
tetracycline discs were placed directly on top of them. Discs were changed every 24 h to 
maintain a high dose of tetracycline delivery to the constructs. Over a 7 days period, visible 
clearing of biofilm occurred within the 1 mm construct below the area of tetracycline 
exposure. (b) CLSM Z-stack images of the 1 mm and 2 mm constructs was performed after 
exposure to tetracycline discs. Whilst the majority of bacteria were found to be dead below 
the area of tetracycline disc exposure in the 1 mm construct, greater evidence of biofilm 
survival in the 2 mm construct was observed. The sizes of the scale bars in the photograph 
are 1 centimetre. 
Conclusions 
In conclusion, mature bacterial biofilm constructs were reproducibly 3D bioprinted for the 
first time using clinically relevant bacteria. By deploying a methodology originally developed 
to enable 3D culture and differentiation of bioprinted stem cells [25], we have been able to 
demonstrate for the first time 3D bioprinted mature biofilm formation, dispersal and 
morphology over 28 days, as well as the antibiotic tolerance of clinically relevant bacterial 
biofilms in 3D. Our methodology also significantly prolongs the viability of bacteria cultured 
in 3D bioprinted constructs compared to previous studies. Future ability to investigate 
clinically relevant bacterial biofilms in a biocompatible, cost-effective 3D model that more 
closely resembles in vivo conditions than traditional 2D culture methods is therefore 
increased.  
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A high degree of control was achieved over biofilm construct thickness and design, with the 
production of biofilms thicker (>4 mm) than currently available in vitro models also achieved. 
We observed that anaerobic bacteria continued to thrive in constructs of greater than 4 mm 
thickness, demonstrating the potency of these infections. To our best knowledge, the 4 mm 
thick aerobic bacteria biofilm formation is the thickest 3D bioprinted in-vitro biofilm construct 
ever reported, allowing easy observation of antimicrobial biofilm penetration.  
We observed that 3D biofilm constructs had greater resistance to antimicrobial treatment 
than 2D cultures, underlining the significance of biofilm formation in clinical infection. Thicker 
biofilms were also seen to have greater resistance to antimicrobial therapy than thinner 
biofilms, even over a prolonged period of treatment.  
With rising worldwide antimicrobial resistance, 3D bioprinted biofilm technology could 
become a key weapon to aid the discovery of novel therapeutic targets and increase the 
understanding of biofilm formation.  
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Determination of bacterial viability in 3D bioprinted constructs 
Three-dimensional (3D) bioprinted biofilms were dissolved in EDTA to be able to enumerate and 
characterise them. Briefly, non-adherent bacteria were removed before by washing the construct 
with PBS then transferring to a new well plate. The constructs were dissolved in 1 ml EDTA (110 mM) 
for 1 h then thoroughly mixed before appropriate dilutions in 9% sodium chloride (NaCl) and plated 
on Brain Heart Infusion (BHI) agar plates and incubated at 37oC overnight to determine viable colony 
forming unites per millilitre (CFU/mL). 
 
 
Figure S1. Enumerate of 3D bioprinted biofilm growth in increasing barium chloride (BaCl2) 
concentration over the period of 5 days. (a) Photo images of construct after dissolved in EDTA 
solution. (b) CFU count in the construct dissolved in EDTA solution.  
 
 
 3 
Long-term stability of printed alginate hydrogels for 3D biofilms 
Cross-linking a sodium alginate hydrogel with calcium chloride created a hydrogel with viscosity 
sufficient to allow bioprinting of free-standing structures ranging in size and thickness. Further 
cross-linking following bioprinting by exposure to solutions of barium chloride helped to maintain 
individual construct stability further, which extended the stability of the hydrogel from within a 
week to over 4 weeks. 
 
Figure S2. Photo images of bacterial constructs over a period of 4 weeks. Growth of MRSA in 1 mm, 
porous scaffolds exposed to increasing concentration of BaCl2 from 10 mM, 20 mM and 40 mM. The 
sizes of the scale bars in the photograph are 1 centimetre. 
 
 
 
  
 4 
Reproducible bioprinting of 3D bacterial biofilms with controlled dimensions 
Successful bioprinting relies in part on combining a suitable bioprinting technique with an 
appropriate bioink. To achieve this, a bacteria-friendly hydrogel was developed with reliable 
bioprinting characteristics. Cross-linking a sodium alginate hydrogel with calcium chloride created a 
hydrogel with viscosity sufficient to allow bioprinting of free-standing structures ranging in size and 
thickness. Further cross-linking following bioprinting by exposure to solutions of barium chloride 
(BaCl2) helped to maintain individual construct stability further. This approach allowed a range of 
construct thicknesses from 0.25 mm to 4 mm to be successfully bioprinted.  
Table S1. Printing parameters before and after BaCl2 crosslinking. Solid and porous constructs with 
vertical thicknesses increasing from 0.25 mm to 4 mm were sequentially bioprinted and cross-linked 
by exposure to 20 mM BaCl2. Measured scaffold thickness following bioprinting correlated well with 
designed thickness prior to and after barium chloride crosslinking.  
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Fluorescence staining for Biofilm viability 
Biofilm viability staining unlisted a commercial Film TracerTM LIVE/DEADTM biofilm viability kit 
(Thermo Fisher) for the assessment of viability is based on the staining with the membrane potential 
sensitive dye propidium iodide (PI) (490 nm excitation, red emission) and the nucleic acid stain SYTO-
9 (488 nm excitation, green emission). Confocal laser Scanning Microscopy (CLSM) was used for 
enumeration and morphological observation of 3D bioprinted biofilm formation. A magnification 
25x water immersion objective was used in all imaging experiments. Images were captured in two-
dimensional (2D) projection. 
 
Figure S3. Confocal laser scanning microscopy (CLSM) images of 3D bioprinted biofilms over a 
period of 28 days. Growth of MRSA in 1 mm, porous scaffolds exposed to increasing concentration 
of BaCl2 from 10 mM to 40 mM. 
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Image processing algorithm and statistical analysis 
The data flow for the algorithm to analyse the 3D reconstruction of the undisturbed biofilm samples 
was carefully considered to make sure that the analysis was robust with respect to the cellular 
physiology and the uncertainty of the signal to noise ratio due to environmental and microscope 
conditions. The algorithm has a main function using unsupervised learning to cluster the data by 
their statistical properties, and it was chosen to apply k-means clustering to deploy automated 
segmentation. There were four benefits: single parameter, no pre-processing, fully automated and 
high accuracy when comparing to conventional thresholding method, which was not robust on non-
uniform or non-flattened images. 
The algorithm was developed using MATLAB 2016a software with its built-in statistics and machine 
learning, and image processing toolboxes. A fixed threshold value and connected volume filtration 
was used for all image stacks. Five image stacks were taken randomly from three independent 
constructs per BaCl2 concentration per time point (15 stacks in total). Firstly, the 2D-projection 
fluorescent images were imported to the software to train the basic algorithm by extracting the 
green channel. An unsupervised k-means segmentation method was applied to the channel, where 
k was set to be 3, which was a suitable value to separate the cellular and background signals. This 
was gained for the technical experience due to uncertainty of signal to noise levels. The calculations 
were on average completed with 3 – 5 seconds from a i7 CPU computer. Once the segments were 
identified, they were then correlated to the fluorescent image to identify the corresponding cellular 
structures. Thirdly, the cells were counted and analysed using the labelling connected component 
method to identify individual microcolony groups. With this method, it was possible to isolate 
groups and when to have no pixelated connection. Finally, the mean and standard deviation of the 
numbers of groups, group areas, and area variations were calculated for statistical purposes.  
 7 
 
Figure S4. Analysis of CLSM z-stacks and adaptive segmented images with calculated total number and total area of 
microcolonies. 
 
Figure S5. Quantification of biofilm formation over time was performed using unsupervised k-means segmentation 
and a labelling connected component function on MATLAB to threshold areas of biofilm formation out from 
background noise on images. The resultant graph of biofilm area produce over time demonstrates that 20 mM and 40 
mM crosslinking provided superior conditions for biofilm formation and with 10 mM found to provide less favourable 
conditions for biofilm formation as compared to 20 mM and 40 mM constructs. 
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Antibiotic selection - Disk diffusion test 
The BHI agar plates were inoculated with E.coli suspension as described in the material and methods 
session (inocula preparation). Briefly, 100 µL of OD 1.0 inoculated suspension was placed on the 
centre of the BHI agar plate and spread evenly over the surface by a L-loop. Antibiotic disks 
containing 30 µg tetracycline (Oxoid), 1U and 10U penicillin (Oxoid) were placed on the plates. The 
agar plates containing the bacteria inoculum and antibiotics disks are further incubated at 37oC for 
24 h.  During the incubation, the antibiotics diffuse into the BHI agar with the antibiotic 
concentration decreasing with increasing distance from the disk. The microbiological determination 
of the inhibition zone sizes is shown in (figure S6), evident inhibitory effect resulting from the 
application of 30 µg tetracycline disk (figure S6A). 
 
 
Figure S6. Disk diffusion test for determine antibiotic susceptibility from the discovery of 
antibiotics. Disk diffusion assays involve placing multiple antibiotic-impregnated disks onto the BHI 
agar surface inoculated with E.coli and measuring the diameter of zones of inhibition to qualitatively 
determine antibiotic susceptibility. (A) Photograph showing lack of E.coli colonies in the vicinity of 
30 µg tetracycline, which is considered to be susceptible to the antibiotic. The bacteria grow within 
the predetermined zone width (B) 1U penicillin and (C) 10U penicillin, which is considered resistant 
to the antibiotic.  
 
 
 
 
 
 
 
 
 
